Showing results (751-760 of 6,300) with videos related to
Sort By:
Pageof 630
Diabetes, Obesity & Metabolism|January 11, 2016
Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargineI Hadjiyianni, D Dahl, L B Lacaya, et al.Diabetes, Obesity & Metabolism|January 11, 2016
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialS Hong, C-Y Park, K A Han, et al.Diabetes, Obesity & Metabolism|November 24, 2015
Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trialH W Rodbard, B Cariou, T R Pieber, et al.Diabetes, Obesity & Metabolism|September 26, 2015
Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibitionS P Rajeev, D J Cuthbertson, J P H WildingDiabetes, Obesity & Metabolism|September 11, 2015
Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetesW Alsalim, A Tura, G Pacini, et al.Diabetes, Obesity & Metabolism|October 30, 2015
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitusW Tang, T A Leil, E Johnsson, et al.Diabetes, Obesity & Metabolism|October 30, 2015
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonistsSten MadsbadDiabetes, Obesity & Metabolism|October 27, 2015
Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreasM M Smits, L Tonneijck, M H A Muskiet, et al.Diabetes, Obesity & Metabolism|January 29, 2016
Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literatureK H Mikkelsen, K H Allin, F K KnopDiabetes, Obesity & Metabolism|February 6, 2016
Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptorV Darsalia, M Larsson, G Lietzau, et al.Pageof 630